Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Net Income towards Common Stockholders: 2009-2025

Historic Net Income towards Common Stockholders for Gyre Therapeutics (GYRE) over the last 16 years, with Sep 2025 value amounting to $3.6 million.

  • Gyre Therapeutics' Net Income towards Common Stockholders rose 221.17% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 107.49%. This contributed to the annual value of $12.1 million for FY2024, which is 113.00% up from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Net Income towards Common Stockholders is $3.6 million, which was up 716.74% from $442,000 recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Net Income towards Common Stockholders ranged from a high of $51.6 million in Q2 2022 and a low of -$101.0 million during Q4 2023.
  • Its 3-year average for Net Income towards Common Stockholders is -$6.7 million, with a median of $2.2 million in 2023.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 453.61% in 2021, then surged by 359.09% in 2022.
  • Gyre Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$20.3 million in 2021, then plummeted by 47.27% to -$29.9 million in 2022, then slumped by 237.70% to -$101.0 million in 2023, then surged by 99.90% to -$99,000 in 2024, then spiked by 221.17% to $3.6 million in 2025.
  • Its Net Income towards Common Stockholders was $3.6 million in Q3 2025, compared to $442,000 in Q2 2025 and $2.7 million in Q1 2025.